Business
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel
About this update from Renovorx, Inc.
[{"type":"text","content":" LOS ALTOS, Calif.--(BUSINESS WIRE)--\nRenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P. The event will be held on Tuesday, May 21, 2024.\n\n\nMr. Bagai will discuss recent corporate milestones, including the completion of private placements in January and April 2024 in which RenovoRx raised $17.2 million in total gross proceeds. The financing provides RenovoRx sufficient funding to advance pivotal Phase III TIGeR-PaC clinical trial, expand development pipeline into additional cancer indications and continue the Company’s ongoing exploration of new commercial business development opportunities with its therapeutic technologies.\n\n\nThe TIGeR-PaC study is evaluating the Company’s lead product candidate, RenovoGem™, and proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for the treatment of locally advanced pancreatic cancer. The second interim analysis for TIGeR-PaC will be triggered by the 52nd event (death), which is estimated to occur in late 2024.\n\n\nA.G.P. Virtual Healthcare Company Showcase:\nDate: Tuesday, May 21, 2024\nTime: 12:00 p.m. – 12:20 p.m. ET\nSpeaker: Shaun Bagai, CEO\nModerator: Scott Henry, AGP Managing Director and Healthcare Analyst\nWebcast: https://us02web.zoom.us/webinar/register/WN_hfErL76eRVquDCCNLXTFDg#/registration\n\n\nTo schedule a one-on-one investor meeting with Mr. Bagai, please reach out to KCSA Strategic Communications at [email protected].\n\n\nA replay of this presentation will be available for at least 30 days following the date of the presentation on the Company’s website at https://ir.renovorx.com/.\n\n\nAbout RenovoRx, Inc.\n\n\nRenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a proprietary local drug-delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precis...